AmyriAD Therapeutics Acquires Recognify Life Sciences, Expanding Its Clinical-Stage Cognition Pipeline with RL-007 (Inidascamine)
All-share transaction: Recognify shareholders – including atai Life Sciences, Catalio Capital Management and Sudhoff Family Office – become shareholders of AmyriAD RL-007 adds a differentiated clinical-stage cognition program in Cognitive Impairment Associated with Schizophrenia (CIAS)...
Covered in this story
Call it yourself
No calls on $ASB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Associated Bancorp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.